PMID- 22614912
OWN - NLM
STAT- MEDLINE
DCOM- 20130124
LR  - 20151119
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 28
IP  - 2
DP  - 2012 Aug
TI  - Efficacy and safety of first-line erlotinib in elderly patients with advanced 
      non-small cell lung cancer.
PG  - 721-7
LID - 10.3892/or.2012.1824 [doi]
AB  - TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study 
      of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable 
      for chemotherapy or radiotherapy received erlotinib 150 mg/day until progression. 
      We examined a subpopulation of elderly patients (>/=70 years) receiving first-line 
      erlotinib (n=485) in TRUST. In this subpopulation, disease control rate (n=356 
      with best response data available) was 79% (vs. 69% for the overall TRUST 
      population; p<0.0001); median progression-free survival (PFS) was 4.57 months 
      [95% confidence interval (CI), 3.68-5.22]; median overall survival (OS) was 7.29 
      months (95% CI, 6.27-8.67); and one-year survival, was 36.6%. PFS and OS were 
      significantly longer in patients developing rash, compared to those without, and 
      in those with good performance status (PS; 0/1), compared to poor PS (>/=2). 
      Eighty-seven subpopulation patients (18%) had an erlotinib-related AE; other than 
      the protocol-defined frequent adverse events (AEs); 4% had a grade >/=3 
      erlotinib-related AE, 7% had an erlotinib-related serious AE. In the 
      subpopulation, dose reductions were required in 27%, most (97%) were reductions 
      to 100 mg/day; treatment was discontinued in 10%, and one death was associated 
      with treatment-related toxicity (<1%). Erlotinib was effective and well-tolerated 
      and may be considered for elderly patients with advanced NSCLC who are unsuitable 
      for standard first-line chemotherapy or radiotherapy.
FAU - Merimsky, Ofer
AU  - Merimsky O
AD  - Division of Oncology, Tel Aviv Medical Center, Tel-Aviv 64239, Israel. 
      oferm@tasmc.health.gov.il
FAU - Cheng, Chi-Kin
AU  - Cheng CK
FAU - Au, Joseph Siu-Kie
AU  - Au JS
FAU - von Pawel, Joachim
AU  - von Pawel J
FAU - Reck, Martin
AU  - Reck M
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120518
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Survival Rate
EDAT- 2012/05/23 06:00
MHDA- 2013/01/25 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/02/16 00:00 [received]
PHST- 2012/03/21 00:00 [accepted]
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2013/01/25 06:00 [medline]
AID - 10.3892/or.2012.1824 [doi]
PST - ppublish
SO  - Oncol Rep. 2012 Aug;28(2):721-7. doi: 10.3892/or.2012.1824. Epub 2012 May 18.